Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma

Highlights • Pancreatic ductal adenocarcinoma (PDAC) is hypovascular. • Vascular endothelial growth factor A (gene: VEGFA) (VEGF-A) is overexpressed in PDAC. • Increased VEGF-A or microvessel density is associated with poor patient outcome. • Blocking VEGF-A in mouse models reduces tumor volumes and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2016-10, Vol.381 (1), p.201-210
Hauptverfasser:	Craven, Kelly E, Gore, Jesse, Korc, Murray
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Angiogenic Proteins - antagonists & inhibitors Angiogenic Proteins - metabolism Animals Carcinoma, Pancreatic Ductal - blood supply Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology Cell division Chemotherapy Clinical trials Confidence intervals Drug Resistance, Neoplasm Endothelium Hematology, Oncology and Palliative Medicine Humans Kinases Metastasis Molecular Targeted Therapy Neovascularization, Pathologic Pancreas Pancreatic cancer Pancreatic Neoplasms - blood supply Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Physiology Proteins Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Receptors, Vascular Endothelial Growth Factor - metabolism Response rates Rodents Signal Transduction - drug effects Tumor Microenvironment Tumorigenesis Tumors Vascular endothelial growth factor Vascular endothelial growth factor (VEGF) Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Pancreatic ductal adenocarcinoma (PDAC) is hypovascular. • Vascular endothelial growth factor A (gene: VEGFA) (VEGF-A) is overexpressed in PDAC. • Increased VEGF-A or microvessel density is associated with poor patient outcome. • Blocking VEGF-A in mouse models reduces tumor volumes and improves survival. • Clinical trials targeting angiogenesis elicit marginal survival benefit.
ISSN:	0304-3835 1872-7980
DOI:	10.1016/j.canlet.2015.11.047